February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Final analysis of the PRECIOUS phase 3 trial
Jan 30, 2025, 08:44

Final analysis of the PRECIOUS phase 3 trial

Paolo Tarantino, Clinical Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared an article by Yutaka Yamamoto, et al. on X:

“Final analysis of the PRECIOUS phase 3 trial out in Journal of Clinical Oncology.

Despite yielding only a small PFS advantage, pertuzumab rechallenge in HER2+ MBC led to a relevant OS benefit (Δ 10 mo). Could become actionable if T-DXd/pertuzumab make it to the first line.”

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.

Authors: Yutaka Yamamoto, et al.

Final analysis of the PRECIOUS phase 3 trial